Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 219, Issue 2, Pages 223-233Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiy482
Keywords
Dengue virus; Zika virus; antibody-dependent enhancement; serological cross-reactivity; vaccine design
Categories
Funding
- National Medical Research Council [0003/2016, 0103/2016]
Ask authors/readers for more resources
Preexisting immunity to Zika virus (ZIKV) or dengue virus (DENV) may alter the course of their infection, and here we use robust mouse models to examine pathological outcomes following passive immunization, sequential cross-infection, or vaccination with inactivated virus. DENV infection was enhanced (through antibody-dependent enhancement [ADE]) or was suppressed by both DENV and ZIKV immunity. Notably, inactivated ZIKV vaccination enhanced dengue disease severity, although it was highly protective against ZIKV infection. On the other hand, ADE was not observed upon ZIKV infection in mice that were passively immunized or preinfected with DENV. Surprisingly, however, we found that vaccination with inactivated DENV enhanced ZIKV infection, mainly in the mesenteric lymph node, indicating the potential for DENV immunity to cause ADE in vivo. Collectively, our data call for greater attention to detail in the design of ZIKV or DENV vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available